Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494584 · ClinicalTrials.gov registry record · Phase 2
Study in Pediatric Subjects With Epilepsy
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01494584 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 5 participants.
The verdict
NCT01494584, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.
Interventions
- DRUG ezogabine/retigabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-07-25 |
| Est. Completion | 2013-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494584
The ClinicalTrials.gov registry entry for NCT01494584 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ezogabine/retigabine is the first listed.
NCT01494584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494584 about?
NCT01494584 is a clinical study titled "Study in Pediatric Subjects With Epilepsy". This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.
What is the current status of trial NCT01494584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-07-25. Estimated completion is 2013-04-29.
What interventions are being tested in trial NCT01494584?
The interventions under investigation include: ezogabine/retigabine (DRUG).
Who is sponsoring clinical trial NCT01494584?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.